2025 United Kingdom Antipsychotic Drugs Revenue Opportunities Report
Description
The 2025 United Kingdom Antipsychotic Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antipsychotic Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the antipsychotic drugs market in the United Kingdom are AstraZeneca PLC, H. Lundbeck A/S, Eli Lilly and Company, and Alkermes PLC. AstraZeneca, headquartered in Cambridge, UK, is a global pharmaceutical giant with a broad portfolio including antipsychotic medications. H. Lundbeck, based in Denmark, specializes in psychiatric and neurological drugs and has developed atypical antipsychotics like sertindole. Eli Lilly, a US-based multinational, markets well-known antipsychotics such as aripiprazole. Alkermes, headquartered in Ireland, focuses on biopharmaceuticals treating psychiatric conditions, with products approved for schizophrenia and bipolar disorder, actively presenting clinical data in 2024.
These companies lead developments and clinical trials in the UK antipsychotic sector. For example, Alkermes recently presented Phase 3 study results for their drug LYBALVI. Otsuka Pharmaceutical and Lundbeck collaborated on trials for brexpiprazole. Aripiprazole, marketed by Eli Lilly and Otsuka, is a key third-generation antipsychotic with improved tolerability. AstraZeneca maintains a significant presence with robust R&D in psychiatric treatments. Collectively, these firms dominate the UK market through extensive product ranges, strategic partnerships, and sustained investment in novel therapies addressing schizophrenia and related disorders.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antipsychotic Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the antipsychotic drugs market in the United Kingdom are AstraZeneca PLC, H. Lundbeck A/S, Eli Lilly and Company, and Alkermes PLC. AstraZeneca, headquartered in Cambridge, UK, is a global pharmaceutical giant with a broad portfolio including antipsychotic medications. H. Lundbeck, based in Denmark, specializes in psychiatric and neurological drugs and has developed atypical antipsychotics like sertindole. Eli Lilly, a US-based multinational, markets well-known antipsychotics such as aripiprazole. Alkermes, headquartered in Ireland, focuses on biopharmaceuticals treating psychiatric conditions, with products approved for schizophrenia and bipolar disorder, actively presenting clinical data in 2024.
These companies lead developments and clinical trials in the UK antipsychotic sector. For example, Alkermes recently presented Phase 3 study results for their drug LYBALVI. Otsuka Pharmaceutical and Lundbeck collaborated on trials for brexpiprazole. Aripiprazole, marketed by Eli Lilly and Otsuka, is a key third-generation antipsychotic with improved tolerability. AstraZeneca maintains a significant presence with robust R&D in psychiatric treatments. Collectively, these firms dominate the UK market through extensive product ranges, strategic partnerships, and sustained investment in novel therapies addressing schizophrenia and related disorders.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
